Genelux (NASDAQ:GNLX) Director John Thomas Sells 10,000 Shares of Stock

Genelux Corporation (NASDAQ:GNLX) Director John Thomas sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $2.98, for a total transaction of $29,800.00. Following the completion of the transaction, the director directly owned 472,784 shares of the company’s stock, valued at $1,408,896.32. This represents a 2.07% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Genelux Stock Performance

Genelux stock opened at $2.95 on Wednesday. The company has a 50 day moving average price of $2.73 and a 200 day moving average price of $3.26. Genelux Corporation has a 52 week low of $2.29 and a 52 week high of $8.53. The firm has a market capitalization of $132.28 million, a price-to-earnings ratio of -3.47 and a beta of 0.56.

Genelux (NASDAQ:GNLX) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.02). Equities analysts forecast that Genelux Corporation will post -0.8 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Genelux

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Woodward Diversified Capital LLC lifted its position in Genelux by 4.8% in the 4th quarter. Woodward Diversified Capital LLC now owns 1,932,711 shares of the company’s stock worth $8,427,000 after buying an additional 88,612 shares in the last quarter. Geode Capital Management LLC lifted its position in Genelux by 7.8% in the 4th quarter. Geode Capital Management LLC now owns 381,407 shares of the company’s stock worth $1,664,000 after buying an additional 27,567 shares in the last quarter. Goldman Sachs Group Inc. lifted its position in Genelux by 451.2% in the 4th quarter. Goldman Sachs Group Inc. now owns 183,807 shares of the company’s stock worth $801,000 after buying an additional 150,463 shares in the last quarter. State Street Corp lifted its position in Genelux by 22.9% in the 4th quarter. State Street Corp now owns 145,850 shares of the company’s stock worth $636,000 after buying an additional 27,200 shares in the last quarter. Finally, Marshall Wace LLP lifted its position in Genelux by 312.3% in the 4th quarter. Marshall Wace LLP now owns 139,148 shares of the company’s stock worth $607,000 after buying an additional 105,402 shares in the last quarter. Hedge funds and other institutional investors own 37.33% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on GNLX shares. Wall Street Zen lowered shares of Genelux from a “hold” rating to a “sell” rating in a research note on Saturday, April 11th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Genelux in a research note on Tuesday, April 21st. Finally, Benchmark cut their target price on shares of Genelux from $23.00 to $20.00 and set a “speculative buy” rating for the company in a research report on Friday, March 20th. Three analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $18.00.

About Genelux

Genelux Corporation (NASDAQ:GNLX) is a clinical-stage biotechnology company focused on the development of oncolytic virus immunotherapies. Built on a proprietary vaccinia virus platform, the company’s programs are designed to selectively infect and destroy cancer cells while stimulating a systemic immune response. Genelux’s lead candidate, pexastimogene devacirepvec (GL-ONC1), is being evaluated in multiple indications, including peritoneal malignancies and head and neck cancers, where it is administered either intraperitoneally or systemically depending on the trial design.

Genelux’s pipeline leverages its experience with the GL-ONC1 construct to explore combination strategies with chemotherapy and immuno-oncology agents.